Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data.

Falutz J, Mamputu JC, Potvin D, Moyle G, Soulban G, Loughrey H, Marsolais C, Turner R, Grinspoon S.

J Clin Endocrinol Metab. 2010 Sep;95(9):4291-304. doi: 10.1210/jc.2010-0490.

PMID:
20554713
2.

Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation.

Falutz J, Allas S, Mamputu JC, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S.

AIDS. 2008 Sep 12;22(14):1719-28. doi: 10.1097/QAD.0b013e32830a5058.

PMID:
18690162
3.

Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.

Falutz J, Potvin D, Mamputu JC, Assaad H, Zoltowska M, Michaud SE, Berger D, Somero M, Moyle G, Brown S, Martorell C, Turner R, Grinspoon S.

J Acquir Immune Defic Syndr. 2010 Mar;53(3):311-22. doi: 10.1097/QAI.0b013e3181cbdaff.

PMID:
20101189
4.

Predictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat.

Mangili A, Falutz J, Mamputu JC, Stepanians M, Hayward B.

PLoS One. 2015 Oct 12;10(10):e0140358. doi: 10.1371/journal.pone.0140358.

5.

Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.

Stanley TL, Feldpausch MN, Oh J, Branch KL, Lee H, Torriani M, Grinspoon SK.

JAMA. 2014 Jul 23-30;312(4):380-9. doi: 10.1001/jama.2014.8334.

6.

Metabolic effects of a growth hormone-releasing factor in patients with HIV.

Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S.

N Engl J Med. 2007 Dec 6;357(23):2359-70.

7.

Growth hormone axis treatments for HIV-associated lipodystrophy: a systematic review of placebo-controlled trials.

Sivakumar T, Mechanic O, Fehmie DA, Paul B.

HIV Med. 2011 Sep;12(8):453-62. doi: 10.1111/j.1468-1293.2010.00906.x. Review.

8.

Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial.

Makimura H, Feldpausch MN, Rope AM, Hemphill LC, Torriani M, Lee H, Grinspoon SK.

J Clin Endocrinol Metab. 2012 Dec;97(12):4769-79. doi: 10.1210/jc.2012-2794.

9.

Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin.

Stanley TL, Falutz J, Marsolais C, Morin J, Soulban G, Mamputu JC, Assaad H, Turner R, Grinspoon SK.

Clin Infect Dis. 2012 Jun;54(11):1642-51. doi: 10.1093/cid/cis251.

10.

A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation.

Falutz J, Allas S, Kotler D, Thompson M, Koutkia P, Albu J, Trottier B, Routy JP, Cote P, Abribat T, Grinspoon S.

AIDS. 2005 Aug 12;19(12):1279-87.

PMID:
16052083
11.

Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy.

Dhillon S.

Drugs. 2011 May 28;71(8):1071-91. doi: 10.2165/11202240-000000000-00000. Review.

PMID:
21668043
12.

Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction.

Stanley TL, Falutz J, Mamputu JC, Soulban G, Potvin D, Grinspoon SK.

AIDS. 2011 Jun 19;25(10):1281-8. doi: 10.1097/QAD.0b013e328347f3f1.

13.

Effects of testosterone supplementation on whole body and regional fat mass and distribution in human immunodeficiency virus-infected men with abdominal obesity.

Bhasin S, Parker RA, Sattler F, Haubrich R, Alston B, Umbleja T, Shikuma CM; AIDS Clinical Trials Group Protocol A5079 Study Team..

J Clin Endocrinol Metab. 2007 Mar;92(3):1049-57.

PMID:
17164307
14.

Spotlight on tesamorelin in HIV-associated lipodystrophy.

Dhillon S.

BioDrugs. 2011 Dec 1;25(6):405-8. doi: 10.2165/11208290-000000000-00000. Review.

PMID:
22050344
15.

Growth hormone-releasing hormone in HIV-infected men with lipodystrophy: a randomized controlled trial.

Koutkia P, Canavan B, Breu J, Torriani M, Kissko J, Grinspoon S.

JAMA. 2004 Jul 14;292(2):210-8.

PMID:
15249570
16.

Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy.

Spooner LM, Olin JL.

Ann Pharmacother. 2012 Feb;46(2):240-7. doi: 10.1345/aph.1Q629. Review.

PMID:
22298602
17.

Low-dose physiological growth hormone in patients with HIV and abdominal fat accumulation: a randomized controlled trial.

Lo J, You SM, Canavan B, Liebau J, Beltrani G, Koutkia P, Hemphill L, Lee H, Grinspoon S.

JAMA. 2008 Aug 6;300(5):509-19. doi: 10.1001/jama.300.5.509.

18.

Recombinant human growth hormone to treat HIV-associated adipose redistribution syndrome: 12 week induction and 24-week maintenance therapy.

Grunfeld C, Thompson M, Brown SJ, Richmond G, Lee D, Muurahainen N, Kotler DP; Study 24380 Investigators Group..

J Acquir Immune Defic Syndr. 2007 Jul 1;45(3):286-97.

PMID:
17592343
19.

Growth hormone-releasing factor agonists for the treatment of HIV-associated lipodystrophy.

Hu M, Tomlinson B.

Curr Opin Investig Drugs. 2010 Oct;11(10):1143-50. Review.

PMID:
20872317
20.

Effects of growth hormone-releasing hormone on bone turnover in human immunodeficiency virus-infected men with fat accumulation.

Koutkia P, Canavan B, Breu J, Grinspoon S.

J Clin Endocrinol Metab. 2005 Apr;90(4):2154-60.

PMID:
15623816
Items per page

Supplemental Content

Support Center